Evidence map›Paper›PMID 42877471›Full record

ReviewJournal of contemporary brachytherapy2026

Three-dimensional-printed template-assisted image-guided brachytherapy for cervical cancer: Technology, dosimetry, and clinical implementation.

Yuanjie Cao, Imashi Sandupama Wickramage, Chen Li, Qingxin Wang, Wenwen Zhang, Youheng Tan, Wenhui Yu, Ying Liu, Wei Wang, Qingsong Pang and 1 more

Abstract readReview
In one paragraph

Review in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuanjie CaoDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Imashi Sandupama WickramageDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Chen LiDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Qingxin WangDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Wenwen ZhangDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Youheng TanSchool of Automation, Central South University, Changsha, Hunan, China.
Wenhui YuDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Ying LiuShangqiu First People's Hospital, Shangqiu, Henan, China.
Wei WangDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Qingsong PangDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Jie ChenDepartment of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Three-dimensional (3D)-printed templates have emerged as practical tools to reduce geometric uncertainty and workflow variability in free-hand intracavitary/interstitial (IC/IS) brachytherapy for cervical cancer. This narrative review aimed to summarize contemporary evidence on 3D-printed templates and applicators, focusing on technology, dosimetry, clinical outcomes, and practical implementation within modern image-guided brachytherapy programs. Material and methods: A narrative literature review with structured search and evidence mapping elements was performed using PubMed and PubMed Central to identify clinical, dosimetric, and technical studies reporting on 3D-printed templates or applicators for cervical or gynecologic brachytherapy between January 2020 and April 2026. The final search was updated on April 28, 2026. Search terms combined cervical cancer, brachytherapy, and 3D printing concepts. Human studies describing device design, imaging and planning approaches, dosimetry, clinical outcomes, or workflow metrics were included, while reference lists of key articles and guidelines were screened to capture influential pre-3D printing mould and hybrid IC/IS series. Data from eligible reports were summarized in structured tables and synthesized qualitatively by theme. Results: Current evidence suggests that 3D-printed templates and applicators can improve the reproducibility of intracavitary/interstitial implantation, and facilitate individualized high-dose-rate or low-dose-rate brachytherapy in anatomically complex primary and recurrent cervical cancer. The reported studies generally showed improved high-risk clinical target volume coverage, higher D Conclusions: Three-dimensional-printed template-assisted brachytherapy represents a clinically relevant strategy for improving implantation reproducibility and supporting individualized image-guided brachytherapy in cervical cancer. Although promising, evidence is still evolving. Wider adoption will require prospective multi-institutional validation, standardized manufacturing and sterilization pathways, robust template-specific quality assurance, and pragmatic implementation models suitable for different clinical settings.

Indexed as

brachytherapycervical cancerimage-guided adaptive brachytherapyintracavitary/interstitial brachytherapythree-dimensional printing

Identifiers

PMID42877471
PMCPMC13662461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.